TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02302430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 International Units Intranasal Oxytocin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Saline nasal spray
Study: NCT04645485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).
Description: Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.
Study: NCT02776020

Intervention type: DEVICE
Intervention: CorrecDose Infrared Monitor
Description: The monitor is attached to patient's wrist and ear in order to measure changes in propofol concentrations in blood
Study: NCT03631108

Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA (ZEISS)
Description: All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens.

Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA (ZEISS)
Description: All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens.
Study: NCT04727749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy Dog Team Visit
Description: For the intervention group, patient interacts with the therapy dog, handler shares information about the therapy dog, asks about patient's pets, and offers a trading card of the therapy dog at the conclusion of the visit.
Study: NCT03491488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Games
Description: The Brain Games intervention package is used as a tool to improve children's self-regulation and executive function skills. Brain Games were developed as part of larger behavioral intervention package in the US, and are designed to build the fundamental self-regulation skills that children need to be successful in school as well as later in life. The games are designed to be played in the classroom between regular activities.
Study: NCT02730806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NLP
Description: NLP techniques, such as VKD, visual/auditory/kinesthetic swishes, modified especially for PTSD, will be implemented one-on-one with each woman in this arm.
Study: NCT01501643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive positive pressure ventilation
Description: At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
Study: NCT01125787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab + bendamustine
Description: Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
Study: NCT02359175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine in epidural catheter
Description: Bupivacain to be given in epidural catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl in epidural catheter
Description: Fentanyl to be given in epidural catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Bupivacain and Fentanyl i epidural catheter)
Description: Saline to be given in epidural catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Paracetamol
Description: Paracetamol to be given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Paracetamol
Description: Paracetamol to be given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral NSAID
Description: NSAID to be given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral NSAID
Description: NSAID to be given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral opioids
Description: Opioids to be given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for oral opioids)
Description: Placebo tablets to be given instead of oral opioids
Study: NCT04335201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide Injection
Description: Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
Study: NCT02661711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye.
Study: NCT02677324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT199
Description: Oral BCL-2 antagonist
Study: NCT01501643

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
Study: NCT01999738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC1456 and EC20
Description: EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging.
Study: NCT01895361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SelG1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SelG1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01595945

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastric bypass
Description: Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caloric restriction
Description: Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
Study: NCT02447783

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Capsules
Description: Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mars Cocoa Extract Capsules
Description: Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
Study: NCT03343964

Intervention type: DIAGNOSTIC_TEST
Intervention: Amplitude-integrated electroencephalography
Description: Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
Study: NCT02530333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Prevention Program
Description: Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
Study: NCT01254344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem sodium
Description: Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone sodium
Description: Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to metronidazole
Description: Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Study: NCT01254344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Study: NCT04744558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carb high fat ketogenic dieting
Description: Macronutrient ratios for low carb high fat ketogenic diet were 20 %, 5 %, 75 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carb high fat non-ketogenic dieting
Description: Macronutrient ratios for low carb high fat non-ketogenic diet were 20 %, 15 %, 65 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
Study: NCT01851096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
Study: NCT01677754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Participants will receive RO4602522 orally once daily for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Participants will receive RO4602522 orally once daily for 12 months.
Study: NCT00467649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate (Symlin)
Description: subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])
Description: subcutaneous injection, dosing based on titration guidelines
Study: NCT01677754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo for RO4602522 orally once daily for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Stable dose as background medication
Study: NCT00467649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Description: subcutaneous injection, dosing based on titration guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Description: subcutaneous injection, dosing based on titration guidelines
Study: NCT00754390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate Calcium, Low phytate Diet
Description: Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
Study: NCT01677754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Stable dose as background medication
Study: NCT00754390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate Calcium, High Phytate Diet
Description: Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
Study: NCT03376555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flow Mediated Dilation with nitroglycerin
Description: BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration.
Study: NCT00754390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Calcium, Low Phytate Diet
Description: Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Calcium, High Phytate Diet
Description: Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
Study: NCT03759275

Intervention type: OTHER
Intervention: pMDT(Baseline Investigation)
Description: The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
Study: NCT03376555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flow Mediated Dilation with nitroglycerin
Description: BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration.
Study: NCT01677754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Stable dose as background medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Stable dose as background medication in combination with AChEIs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Stable dose as background medication in combination with AChEIs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Stable dose as background medication in combination with AChEIs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine
Description: Stable dose as background medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Stable dose as background medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Stable dose as background medication
Study: NCT01677754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine
Description: Stable dose as background medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Stable dose as background medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Stable dose as background medication
Study: NCT02069158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: iv administrartion
Study: NCT03490981

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)
Description: Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
Study: NCT02766842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with ProCore needle
Description: The use of the standard ProCore needle to acquire diagnostic tissue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with SharkCore needle
Description: The use of new SharkCore needle to acquire diagnostic tissue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProCore needle
Description: This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SharkCore needle
Description: This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
Study: NCT02726308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 5 mg I.V. Dexamethasone just before induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 5 mg I.V. Dexamethasone just before induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 ml/kg Ringer's lactate
Description: Intra-operative 10 ml/kg Ringer's lactate solution .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 ml/kg Ringer's lactate
Description: Intra-operative 30 ml/kg Ringer's lactate solution .
Study: NCT05457894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M, Inactivated split influenza vaccine
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M, Inactivated split influenza vaccine
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrix®, Inactivated Split Influenza Vaccine
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrix®, Inactivated Split Influenza Vaccine
Description: solution for intramuscular injection, 0.5 ml
Study: NCT03500185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT in group
Description: Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT at home
Description: Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
Study: NCT00260442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 12 weeks, 3 times a week whole body resistance training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 12 weeks, 3 times a week whole body resistance training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: 12 weeks, 3 times a week whole body resistance training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary
Description: Absence of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary
Description: Absence of physical activity
Study: NCT03376555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flow Mediated Dilation with nitroglycerin
Description: BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flow Mediated Dilation with nitroglycerin
Description: BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration.
Study: NCT00260442

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sedentary
Description: Absence of physical activity
Study: NCT01856764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Roflumilast Cream
Description: Roflumilast 0.5% cream
Study: NCT00444184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost/timolol fixed combination, travoprost

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost/timolol fixed combination, travoprost
Study: NCT02585427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil
Study: NCT01856764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Roflumilast formulation vehicle
Study: NCT02724670

Intervention type: RADIATION
Group type: OTHER
Intervention: IGRT
Description: MR-based IGRT